Bioengineered Vaccine Adjuvants

描述（由申请人提供）：我们计划开发一个新的家庭， 疫苗佐剂通过生物工程的微生物糖脂。这种聚合物 这种物质是由细菌不动杆菌分泌的产物 在初步研究中， 活动为了进一步探索这一应用，我们计划将结构 具有体外巨噬细胞反应和抗体反应的聚合物的特征 一系列的类似物。I期研究将确定 巨噬细胞反应的性质是结构特异性的，如果是这样， 结构特征是最重要的。这些特征将在 在鼠莱姆病疫苗模型中体内。为了实现这一目标，我们将创建一个 使用我们最近开发的方法， 表征这些类似物对巨噬细胞反应的选择性， 细胞因子释放后体内抗体反应。阶段的结果 我将是一个最好的几个候选结构选择前进到 更详细的体内试验在第二阶段。 拟定商业应用： 结构相关的疫苗佐剂家族的开发是相当重要的 与建立结构-性质关系和定制治疗相关。

DESCRIPTION (Provided by Applicant): We plan to develop a novel family of vaccine adjuvants through bioengineering a microbial glycolipid. This polymeric material is generated as a secreted product from the bacterium, Acinetobacter calcoaceticus and in preliminary studies demonstrates exceptional adjuvant activity. To further explore this application, we plan to correlate structural features of the polymer with macrophage response in vitro and antibody response in vivo to a series of these analogs. The Phase I studies will determine if the nature of the macrophage response is structure-specific, and if so, which structural features are most important. These features will then be assessed in vivo in a murine Lyme vaccine model. To accomplish this goal we will generate a family of structural analogs using methods we have recently developed, and then characterize these analogs for selectivity of responses of macrophages in terms of cytokine release followed by antibody response in vivo. The outcome of Phase I will be a selection of the best few candidate structures to move forward into more detailed in vivo testing in Phase II. PROPOSED COMMERCIAL APPLICATION: The development of a family of structurally related vaccine adjuvants is of considerable relevance for establishing structure-property relations and tailored therapeutics.